Moody Lynn & Lieberson’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $38.3M | Sell |
176,293
-16,170
| -8% | -$3.59M | 2.15% | 15 |
|
|
2025
Q4 | $44M | Buy |
192,463
+9,001
| +5% | +$2.05M | 2.33% | 13 |
|
|
2025
Q3 | $42.5M | Buy |
183,462
+11,085
| +6% | +$2.26M | 2.29% | 14 |
|
|
2025
Q2 | $32M | Buy |
172,377
+4,208
| +3% | +$782K | 1.85% | 19 |
|
|
2025
Q1 | $35.2M | Buy |
168,169
+12,217
| +8% | +$2.38M | 2.26% | 15 |
|
|
2024
Q4 | $27.7M | Sell |
155,952
-25,213
| -14% | -$4.64M | 1.7% | 17 |
|
|
2024
Q3 | $35.8M | Buy |
181,165
+25,850
| +17% | +$4.82M | 2.2% | 14 |
|
|
2024
Q2 | $26.6M | Sell |
155,315
-17,823
| -10% | -$2.95M | 1.74% | 16 |
|
|
2024
Q1 | $31.5M | Buy |
173,138
+69,276
| +67% | +$11.9M | 2.12% | 14 |
|
|
2023
Q4 | $16.1M | Buy |
103,862
+514
| +0.5% | +$74.9K | 1.22% | 27 |
|
|
2023
Q3 | $15.4M | Buy |
103,348
+1,267
| +1% | +$186K | 1.32% | 29 |
|
|
2023
Q2 | $13.8M | Buy |
102,081
+4,494
| +5% | +$659K | 1.11% | 29 |
|
|
2023
Q1 | $15.6M | Sell |
97,587
-16,770
| -15% | -$2.56M | 1.4% | 26 |
|
|
2022
Q4 | $18.5M | Sell |
114,357
-758
| -0.7% | -$116K | 1.69% | 24 |
|
|
2022
Q3 | $15.4M | Sell |
115,115
-39,383
| -25% | -$5.65M | 1.49% | 26 |
|
|
2022
Q2 | $23.7M | Sell |
154,498
-957
| -0.6% | -$146K | 2.13% | 12 |
|
|
2022
Q1 | $25.2M | Buy |
155,455
+15,869
| +11% | +$2.31M | 1.85% | 17 |
|
|
2021
Q4 | $18.9M | Buy |
139,586
+135,024
| +2,960% | +$15.9M | 1.27% | 30 |
|
|
2021
Q3 | $492K | Buy |
4,562
+195
| +4% | +$22.3K | 0.04% | 157 |
|
|
2021
Q2 | $492K | Sell |
4,367
-43
| -1% | -$4.84K | 0.04% | 154 |
|
|
2021
Q1 | $477K | Buy |
4,410
+34
| +0.8% | +$3.64K | 0.04% | 160 |
|
|
2020
Q4 | $469K | Buy |
4,376
+1,000
| +30% | +$96.1K | 0.04% | 150 |
|
|
2020
Q3 | $296K | Hold |
3,376
| – | – | 0.03% | 165 |
|
|
2020
Q2 | $331K | Hold |
3,376
| – | – | 0.04% | 148 |
|
|
2020
Q1 | $257 | Buy |
+3,376
| New | +$288K | 0.04% | 145 |
|
|
2019
Q1 | – | Sell |
-2,332
| Closed | -$215K | – | 186 |
|
|
2018
Q4 | $215K | Sell |
2,332
-750
| -24% | -$66K | 0.03% | 183 |
|
|
2018
Q3 | $291K | Buy |
3,082
+285
| +10% | +$27K | 0.03% | 186 |
|
|
2018
Q2 | $259K | Sell |
2,797
-138
| -5% | -$13.5K | 0.03% | 196 |
|
|
2018
Q1 | $278K | Buy |
2,935
+138
| +5% | +$15.2K | 0.03% | 184 |
|
|
2017
Q4 | $324K | Buy |
2,797
+200
| +8% | +$18.8K | 0.03% | 191 |
|
|
2017
Q3 | $231K | Buy |
+2,597
| New | +$198K | 0.03% | 203 |
|
|
2015
Q1 | – | Sell |
-25,153
| Closed | -$1.65M | – | 182 |
|
|
2014
Q4 | $1.65M | Buy |
+25,153
| New | +$1.59M | 0.23% | 86 |
|
|
2013
Q3 | – | Sell |
-137,156
| Closed | -$5.67M | – | 181 |
|
|
2013
Q2 | $5.67M | Buy |
+137,156
| New | +$6M | 0.99% | 41 |
|
Other funds holding ABBV
VCM
VPM
Moody Lynn & Lieberson's ABBV Position: Q1 2026 in Review
Moody Lynn & Lieberson reduced its AbbVie (ABBV) stake by 8.4% in Q1 2026, selling an estimated $3.59M and leaving 176,293 shares worth $38.3M. The position accounts for 2.15% of the portfolio, ranked #15.
Moody Lynn & Lieberson first reported a position in ABBV in Q2 2013 and has held it in 33 quarters since. The position peaked at $44M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Moody Lynn & Lieberson held 176,293 shares of AbbVie worth $38.3M as of Q1 2026.
- Moody Lynn & Lieberson sold 16,170 AbbVie shares in Q1 2026, an estimated $3.59M.
- AbbVie made up 2.15% of Moody Lynn & Lieberson's portfolio in Q1 2026, its #15 holding.
- Moody Lynn & Lieberson first reported a position in AbbVie in Q2 2013 and has held it in 33 quarters since.
- Moody Lynn & Lieberson's AbbVie position peaked at $44M in Q4 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Moody Lynn & Lieberson's 13F filing for Q1 2026, filed 13 Apr 2026.